All the news Showing 10 of 248 articles from: Interferon-free regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Merck press release / 29 January 2016 Three-drug regimens taken for 8 weeks demonstrate high hepatitis C cure rate Liz Highleyman / 13 January 2016 An interferon-free regimen containing Merck's grazoprevir, the NS5A inhibitors elbasvir or MK8404, and the experimental nucleotide polymerase inhibitor MK-3682, taken for 8 weeks, cured more than 90% of hepatitis C ... Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir/Velpatasvir for Treatment of All Genotypes of Chronic Hepatitis C Infection Gilead press release / 05 January 2016 AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® AbbVie press release / 02 December 2015 Sofosbuvir + daclatasvir demonstrates high cure rates for people with HIV and HCV co-infection Liz Highleyman / 29 October 2015 Nearly all people with HIV and genotype 1-4 HCV co-infection treated for 12 weeks with an interferon-free regimen of sofosbuvir (Sovaldi) plus daclatasvir (Daklinza) achieved sustained virological response in the ALLY-2 trial, ... Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes Gilead press release / 21 September 2015 Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission Bristol-Myers Squibb press release / 15 September 2015 Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® + EXVIERA® in Genotype 1 Hepatitis C Patients AbbVie press release / 14 September 2015 FDA OK's BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3 Manual Items / 27 July 2015 FDA approves Technivie for treatment of chronic hepatitis C genotype 4 FDA / 27 July 2015 ← Prev1...34567...25Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive